We are live on
!
Find out more
RhumbLine Advisers Portfolio holdings
AUM
$117B
1-Year Est. Return
29.66%
This Fund
S&P 500
This Quarter
Est. Return
+9.63%
1 Year Est. Return
+29.66%
3 Year Est. Return
+101.47%
5 Year Est. Return
+137.35%
10 Year Est. Return
+530.92%
AUM
$59.8B
AUM Growth
+$5.07B
(+9.3%)
Cap. Flow
+$518M
Cap. Flow
% of AUM
0.87%
Top 10 Holdings %
Top 10 Hldgs %
18.08%
Holding
2,992
New
38
Increased
2,357
Reduced
537
Closed
43
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$68M |
| 2 |
Truist Financial
TFC
|
+$55.9M |
| 3 |
ServiceNow
NOW
|
+$33.3M |
| 4 |
Uber
UBER
|
+$21.4M |
| 5 |
Las Vegas Sands
LVS
|
+$15.7M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
CELG
Celgene Corp
CELG
|
+$119M |
| 2 |
STI
SunTrust Banks, Inc.
STI
|
+$55.9M |
| 3 |
Apple
AAPL
|
+$48.3M |
| 4 |
iShares TIPS Bond ETF
TIP
|
+$22M |
| 5 |
VIAB
Viacom Inc. Class B
VIAB
|
+$16.4M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 19.57% |
| 2 | Financials | 15.53% |
| 3 | Healthcare | 13.38% |
| 4 | Consumer Discretionary | 10.07% |
| 5 | Industrials | 9.99% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
CARO
1926
DELISTED
Carolina Financial Corp.
CARO
| $1.44M | ﹤0.01% |
33,360
+655
| +2% | +$25.8K |
|
1927
Atlanta Braves Holdings Series B
BATRK
$3.13B
| $1.44M | ﹤0.01% |
48,750
+606
| +1% | +$17.2K |
|
1928
Columbia Financial
CLBK
$1.13B
| $1.44M | ﹤0.01% |
85,014
+1,438
| +2% | +$23.7K |
|
|
VIVO
1929
DELISTED
Meridian Bioscience Inc
VIVO
| $1.43M | ﹤0.01% |
146,338
+6,291
| +4% | +$59.1K |
|
1930
Columbus McKinnon
CMCO
$599M
| $1.43M | ﹤0.01% |
35,635
+1,639
| +5% | +$63.4K |
|
|
CHUY
1931
DELISTED
Chuy's Holdings, Inc. Common Stock
CHUY
| $1.42M | ﹤0.01% |
54,935
+2,550
| +5% | +$66.1K |
|
|
MODN
1932
DELISTED
MODEL N, INC.
MODN
| $1.42M | ﹤0.01% |
40,577
+1,846
| +5% | +$56.2K |
|
|
RAD
1933
DELISTED
Rite Aid Corporation
RAD
| $1.42M | ﹤0.01% |
91,967
+2,350
| +3% | +$23K |
|
|
PGNX
1934
DELISTED
Progenics Pharmaceuticals Inc
PGNX
| $1.42M | ﹤0.01% |
279,303
+18,508
| +7% | +$97.9K |
|
1935
MarineMax
HZO
$776M
| $1.42M | ﹤0.01% |
85,119
+2,409
| +3% | +$39.3K |
|
1936
Stoneridge
SRI
$205M
| $1.42M | ﹤0.01% |
48,480
+173
| +0.4% | +$5.33K |
|
1937
PJT Partners
PJT
$4.42B
| $1.42M | ﹤0.01% |
31,468
+453
| +1% | +$19K |
|
1938
Motorcar Parts of America
MPAA
$257M
| $1.42M | ﹤0.01% |
64,364
+3,508
| +6% | +$67.8K |
|
1939
Middlesex Water
MSEX
$1.08B
| $1.42M | ﹤0.01% |
22,300
+340
| +2% | +$21.5K |
|
1940
Forrester Research
FORR
$233M
| $1.41M | ﹤0.01% |
33,911
+2,195
| +7% | +$81.8K |
|
|
ROCC
1941
DELISTED
Ranger Oil Corporation Class A Common Stock
ROCC
| $1.41M | ﹤0.01% |
46,365
+3,040
| +7% | +$80.9K |
|
1942
Primoris Services
PRIM
$4.35B
| $1.4M | ﹤0.01% |
63,125
+671
| +1% | +$14.4K |
|
|
TWOU
1943
DELISTED
2U Inc
TWOU
| $1.4M | ﹤0.01% |
1,940
-9
| -0.5% | -$5.6K |
|
|
BMTC
1944
DELISTED
Bryn Mawr Bank Corp
BMTC
| $1.39M | ﹤0.01% |
33,724
+554
| +2% | +$21.4K |
|
1945
Allogene Therapeutics
ALLO
$680M
| $1.38M | ﹤0.01% |
53,224
+1,814
| +4% | +$50K |
|
1946
Liberty Latin America Class A
LILA
$1.75B
| $1.38M | ﹤0.01% |
111,724
+1,091
| +1% | +$12.7K |
|
1947
Trupanion
TRUP
$1.23B
| $1.38M | ﹤0.01% |
36,729
+698
| +2% | +$20.5K |
|
|
HTBK
1948
DELISTED
Heritage Commerce
HTBK
| $1.37M | ﹤0.01% |
107,092
+10,692
| +11% | +$130K |
|
1949
Insteel Industries
IIIN
$626M
| $1.37M | ﹤0.01% |
63,864
+3,052
| +5% | +$64.5K |
|
|
SGMO
1950
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
| $1.37M | ﹤0.01% |
163,594
+7,174
| +5% | +$66K |
|
Similar funds
VAM
RhumbLine Advisers's Q4 2019 Portfolio in Review
As of Q4 2019, RhumbLine Advisers held 2,992 positions worth $59.8B, up 9.3% from $54.7B the previous quarter. Its ten largest holdings account for 18% of the portfolio.
Trading was light in Q4 2019: portfolio turnover was 2.7%. RhumbLine Advisers opened 38 new positions and exited 43, leaving the 2,992-position portfolio largely intact.
By sector, the portfolio is most concentrated in Technology at 20% of assets, up from 19% a quarter earlier, followed by Financials and Healthcare.
- RhumbLine Advisers's largest Q4 2019 buy was Envista: 126,664 shares worth $3.75M.
- RhumbLine Advisers added most to Bristol-Myers Squibb in Q4 2019, an estimated $68M increase.
- RhumbLine Advisers's biggest Q4 2019 reduction was Apple, cutting an estimated $48.3M.
- RhumbLine Advisers fully exited Celgene Corp in Q4 2019, selling an estimated $119M.
- RhumbLine Advisers's ten largest holdings make up 18% of its $59.8B portfolio in Q4 2019.
- RhumbLine Advisers opened 38 new positions and closed 43 in Q4 2019.
- RhumbLine Advisers's portfolio value rose 9.3% quarter-over-quarter to $59.8B.
Based on RhumbLine Advisers's 13F filing for Q4 2019, filed 5 Feb 2020.